NuCana (NCNA) Competitors

NuCana (NASDAQ:NCNA) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, community ranking, valuation, profitability, dividends and risk.

Do analysts prefer NCNA or BPTH?

NuCana presently has a consensus price target of $25.00, suggesting a potential upside of 17,795.49%. Bio-Path has a consensus price target of $20.00, suggesting a potential upside of 10,052.28%. Given NuCana's higher probable upside, analysts clearly believe NuCana is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals and insiders hold more shares of NCNA or BPTH?

44.0% of NuCana shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 31.2% of NuCana shares are owned by company insiders. Comparatively, 0.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Is NCNA or BPTH more profitable?

NuCana's return on equity of -314.47% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-314.47%	-112.60%
Bio-Path	N/A	-2,842.40%	-337.48%

Does the media favor NCNA or BPTH?

In the previous week, Bio-Path had 7 more articles in the media than NuCana. MarketBeat recorded 9 mentions for Bio-Path and 2 mentions for NuCana. NuCana's average media sentiment score of 0.93 beat Bio-Path's score of -0.06 indicating that NuCana is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NuCana	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Path	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor NCNA or BPTH?

Bio-Path received 31 more outperform votes than NuCana when rated by MarketBeat users. However, 67.65% of users gave NuCana an outperform vote while only 52.32% of users gave Bio-Path an outperform vote.

Company	Underperform	Outperform
NuCana	Outperform Votes 251 67.65%	Underperform Votes 120 32.35%
Bio-Path	Outperform Votes 282 52.32%	Underperform Votes 257 47.68%

Which has more volatility and risk, NCNA or BPTH?

NuCana has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, Bio-Path has a beta of -0.05, suggesting that its stock price is 105% less volatile than the S&P 500.

Which has preferable earnings and valuation, NCNA or BPTH?

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$34.37M	-$7.02	-0.02
Bio-Path	N/A	N/A	-$16.08M	N/A	N/A

Summary

NuCana beats Bio-Path on 8 of the 12 factors compared between the two stocks.